Newsletters arkiv förslag
Alternativ 1
-
Newsletter #2 – 2025
Read more: Newsletter #2 – 2025 -
Newsletter #1 – 2025
Read more: Newsletter #1 – 2025 -
Newsletter #2 – 2024
Read more: Newsletter #2 – 2024 -
Newsletter #1 – 2024
Read more: Newsletter #1 – 2024 -
Newsletter #1 – 2023
Read more: Newsletter #1 – 2023 -
Newsletter #2 – 2022
Read more: Newsletter #2 – 2022
Alternativ 2
Alternative 2
Newsletter #2 – 2022
The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE PHARMA – Update on Novartis v Zentiva, Glenmark, Teva, and Mylan over fingolimod products PHARMA – Teva v Bristol-Myers Squibb over the validity of apixaban…
Newsletter #1 – 2022
The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE Pharma: Novartis v Zentiva over generic fingolimod product Medtech: Edwards Lifesciences v Meril Life Sciences over transcatheter heart valves Life sciences: Illumina v MGI over…